Healthcare Global Anti-Viral Drug Market | страница 3

Rising Prevalence of Chronic Diseases
Significant growth in the number of patients suffering from chronic
diseases is expanding the market of anti-viral drugs. As per World Health
Organization, 36.7 million HIV cases and 71 million hepatitis C cases were
registered in 2016. Further, more than 95% people suffering from hepatitis
C can be treated by anti-viral medications. These factors are likely to
augment the growth of anti-viral drugs market.
Favourable Government Initiatives
Government policies and programs to limit chronic diseases fatalities are
anticipated to be the dynamic factor behind the growth of the anti-viral
drug market during the forecast period. For instance, U.S. government has
launched National Viral Hepatitis Action Plan to improve the life of people
suffering from hepatitis which is likely to augment the demand for anti-
viral drugs in the overcoming years. Although, high cost associated with
the development of anti-viral drugs and lack of diagnostic centers and
hospitals in undeveloped nations are some of the factors that are likely to
inhibit the growth of the Global Anti-Viral Drug Market in the near future.
Request For TOC
request/1/rep-id-473
Here:
https://www.researchnester.com/toc-
The report titled “Anti-Viral Drug Market : Global Historical
Growth (2012-2016) & Future Outlook (2017-2024) Demand
Analysis & Opportunity Evaluation” delivers detailed overview of the
Global anti-viral drug market in terms of market segmentation by type, by
application, by end user and by region. Further, for the in-depth analysis,
the report encompasses the industry growth drivers, restraints, supply and
demand risk, market attractiveness, BPS analysis and Porter’s five force
model.
This report also provides the existing competitive scenario of some of the
key players of the global anti-viral drug market which includes company
profiling of GlaxoSmithKline PLC, Johnson and Johnson, Merck & Co,
Abbott Laboratories, Cipla Limited, F. Hoffmann-La Roche Ltd., Bristol-
Myers-Squibb, Gilead Sciences, Aurobindo Pharma and Sino
Copyright © Research Nester
www.researchnester.com